First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma
Full text links
Publisher website (DOI) 10.1093/annonc/mdy020
Europe PubMed Central 29360923
Pubmed 29360923
Keywords
Related topics
Type of publication